Encompass Health Co. (NYSE:EHC) CEO Mark J. Tarr Sells 44,976 Shares

Encompass Health Co. (NYSE:EHC) CEO Mark J. Tarr sold 44,976 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total value of $3,745,151.52. Following the transaction, the chief executive officer now directly owns 554,098 shares in the company, valued at approximately $46,139,740.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Encompass Health Stock Down 0.6 %

NYSE EHC opened at $82.84 on Thursday. The business has a fifty day moving average price of $78.64 and a two-hundred day moving average price of $71.25. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.37 and a quick ratio of 1.28. Encompass Health Co. has a fifty-two week low of $57.55 and a fifty-two week high of $85.84. The stock has a market capitalization of $8.30 billion, a PE ratio of 22.39, a PEG ratio of 1.30 and a beta of 0.92.

Encompass Health (NYSE:EHC) last released its earnings results on Wednesday, April 24th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.19. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The firm had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.27 billion. During the same period in the prior year, the company earned $0.88 earnings per share. The company’s quarterly revenue was up 13.4% on a year-over-year basis. Equities analysts expect that Encompass Health Co. will post 4.1 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Monday, April 1st were paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.72%. The ex-dividend date was Thursday, March 28th. Encompass Health’s payout ratio is 16.22%.

Analysts Set New Price Targets

Several research firms have recently commented on EHC. Stephens reaffirmed an “overweight” rating and issued a $85.00 target price on shares of Encompass Health in a research report on Tuesday, January 16th. Barclays upped their target price on Encompass Health from $101.00 to $108.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. Truist Financial upped their target price on Encompass Health from $82.00 to $86.00 and gave the company a “buy” rating in a research report on Friday, February 9th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $83.00 target price on shares of Encompass Health in a research report on Friday, February 9th. Finally, Raymond James reiterated a “strong-buy” rating and issued a $95.00 price target (up from $85.00) on shares of Encompass Health in a research note on Friday, April 26th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $90.29.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Encompass Health by 4.7% in the 4th quarter. Vanguard Group Inc. now owns 9,997,034 shares of the company’s stock valued at $667,002,000 after acquiring an additional 450,081 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Encompass Health by 5.8% in the 4th quarter. Wellington Management Group LLP now owns 8,215,770 shares of the company’s stock valued at $548,156,000 after acquiring an additional 449,230 shares during the last quarter. William Blair Investment Management LLC lifted its stake in shares of Encompass Health by 6.4% in the 3rd quarter. William Blair Investment Management LLC now owns 5,676,379 shares of the company’s stock valued at $381,226,000 after acquiring an additional 342,512 shares during the last quarter. Invesco Ltd. increased its holdings in Encompass Health by 22.3% in the third quarter. Invesco Ltd. now owns 3,974,306 shares of the company’s stock valued at $266,914,000 after purchasing an additional 724,544 shares during the period. Finally, TD Asset Management Inc increased its holdings in Encompass Health by 239.6% in the fourth quarter. TD Asset Management Inc now owns 1,969,186 shares of the company’s stock valued at $131,384,000 after purchasing an additional 1,389,275 shares during the period. 97.25% of the stock is currently owned by institutional investors.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.